Recreational Drugs and HIV Antiretrovirals. A Guide to Interactions for Clinicians
|
|
|
- David Barton
- 6 years ago
- Views:
Transcription
1 Recreational Drugs and HIV Antiretrovirals A Guide to Interactions for Clinicians 2009
2 Recreational Drugs and HIV Antiretrovirals A Guide to Interactions for Clinicians Prepared by: Antonio Urbina, MD, John Faragon, PharmD, BCPS, AAHIVE, Christine Kubin, PharmD and Audrey Castillo, MPH. This clinical support tool is sponsored by the New York/New Jersey AIDS Education Training Center (NY/NJ AETC).The NY/NJ AETC is funded by the Health Resources and Services Administration (HRSA) and is part of the National AIDS Education Training Center Program, a network of federally funded regional and national centers that conduct targeted multidisciplinary HIV/AIDS education and training programs for health care providers. Disclaimer: Neither the AIDS Education and Training Centers nor HRSA condone or recommend the use of illicit drugs in any context. The data in this guide are intended for use by clinicians and other health care providers to provide advice that may reduce harm to patients who use these substances in conjunction with antiretroviral agents. The data in this guide are a compilation of information obtained from published and anecdotal studies through November PLEASE REFER TO PAGE 10 OF THIS GUIDE FOR IMPORTANT HARM REDUCTION THAT SHOULD BE SHARED WITH PATIENTS. 2 NY/NJ AIDS Education and Training Center Columbia University College of Physicians and Surgeons 100 Haven Avenue, Suite 31G New York, NY nynjaetc@columbia.edu
3 ALCOHOL Confusion, disorientation, incoordination, loss of GENERAL balance and judgement, respiratory depression, stupor, coma PHARMACOKINETICS Metabolized by alcohol dehydrogenase and aldehyde dehydrogenase; alcohol may induce CYP2E1 and CYP3A N delavirdine (Rescriptor) No known interactions specific to nevirapine (Viramune) etravirine (Intelence) abacavir (ABC,Ziagen) Increases abacavir AUC ~40% (decreased abacavir metabolism by alcohol dehydrogenase) didanosine (ddl, Videx) Increased risk of pancreatitis emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) SEE INDIVIDUAL COMPONENTS tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) Protease Inhibitors amprenavir (Agenerase) No known interactions specific to. fosamprenavir (Lexiva) Caution with amprenavir and fosamprenavir oral solution atazanavir (Reyataz) as increased risk of propylene glycol toxicity possible. darunavir (Prezista) lopinavir/ritonavir (Kaletra) nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) No known interactions specific to Raltegravir (Isentress) No known interactions specific to AMPHETAMINES (Crystal) Paranoia, anxiety, depression, hallucinations, tachycardia, hypertension, stroke, myocardial infarction, hyperthermia, rhabdomyolysis, diarrhea, erectile dysfunction, teeth grinding Metabolized by hydroxylation and deamination via CYP2D6 pathway; CYP2D6 inhibitors may increase amphetamine levels (try to avoid) N delavirdine (Rescriptor) nevirapine (Viramune) etravirine (Intelence) abacavir (ABC,Ziagen) didanosine (ddl, Videx) emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) Protease Inhibitors amprenavir (Agenerase) fosamprenavir (Lexiva) atazanivir (Reyataz) darunavir (Prezista) lopinavir/ritonavir (Kaletra) nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) Raltegravir (Isentress) No known interactions specific to SEE INDIVIDUAL COMPONENTS Use of full dose ritonavir or low dose ritonavir for boosting other protease inhibitors has the potential to increase amphetamine levels in the blood. No known interactions specific to this combination. Refer to comments for this drug class in general Increases amphetamine blood levels 2-3 times No known interactions specific to No known interactions specific to 3
4 GENERAL PHARMACOKINETICS N delavirdine (Rescriptor) nevirapine (Viramune) etravirine (Intelence) abacavir (ABC,Ziagen) didanosine (ddl, Videx) emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) Protease Inhibitors amprenavir (Agenerase) fosamprenavir (Lexiva) atazanivir (Reyataz) darunavir (Prezista) lopinavir/ritonavir (Kaletra) nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) 4 Raltegravir (Isentress) AMYL NITRITE (amyl nitrate, poppers) Reduces glutathioine levels; inhaling the fumes acts as a vasodilator (hypotension, tachycardia, headaches), skin flushing No known interactions specific to this combination SEE INDIVIDUAL COMPONENTS No known interactions No known interactions specific to No known interactions specific to BENZODIAZEPINES CNS depression, drowsiness, memory loss, impaired coordination Most agents extensively metabolized in the liver by the CYP3A4 system; lorazepam, oxazepam, and temazepam metabolized by conjugation via glucuronidation. N delavirdine (Rescriptor) nevirapine (Viramune) etravirine (Intelence) abacavir (ABC,Ziagen) didanosine (ddl, Videx) emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) Protease Inhibitors amprenavir (Agenerase) fosamprenavir (Lexiva) atazanivir (Reyataz) darunavir (Prezista) lopinavir/ritonavir (Kaletra) nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) Raltegravir (Isentress) Likely inhibits benzodiazepine metabolism through CYP3A4 inhibition and increases risk of adverse effects; concomitant use should be avoided No known interactions specific to this combination Diazepam drug levels may be increased by etravirine; a decrease in diazepam dosage may be needed SEE INDIVIDUAL COMPONENTS Likely to interfere with metabolism and increase AUC of benzodiazepines; use of PIs with benzodiazepines should be avoided due to increased risk of sedation and respiratory depression; midazolam and triazolam specifically contraindicated with all PIs. DHHS guidelines recommend that parenteral midazolam can be used with caution as a single dose if given in a monitored situation for procedural sedation. No known interactions specific to this combination. Refer to comments for this drug class in general Decreases therapeutic effect of lorazepam, oxazepam, and temazepam (monitor for withdrawal) No known interactions specific to No known interactions specific to
5 GENERAL PHARMACOKINETICS Mainly metabolized by nonspecific tissue and plasma esterases; some cocaine metabolism ( 10%) via CYP3A4 N delavirdine (Rescriptor) nevirapine (Viramune) No known interactions specific to etravirine (Intelence) abacavir (ABC,Ziagen) didanosine (ddl, Videx) emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) No known interactions Protease Inhibitors amprenavir (Agenerase) fosamprenavir (Lexiva) atazanivir (Reyataz) darunavir (Prezista) lopinavir/ritonavir (Kaletra) nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) Raltegravir (Isentress) COCAINE (coke, blow) Increases rate of HIV viral replication in vitro, hypertension, cardiac dysrhythmias, myocardial infarction, seizures, depression, anxiety SEE INDIVIDUAL COMPONENTS No known interactions specific to No known interactions specific to ECSTASY (X, MDMA) Tachycardia, hypertension, hyperthermia, dehydration, dry mouth, tense jaw, teeth grinding, depression CYP2D6 demethylation important in metabolism; 2D6 inhibitors are likely to increase ecstasy levels N delavirdine (Rescriptor) nevirapine (Viramune) No known interactions specific to this etravirine (Intelence) combination abacavir (ABC,Ziagen) didanosine (ddl, Videx) SEE INDIVIDUAL COMPONENTS emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) Increase levels of ecstasy zidovudine (AZT, ZDV, Retrovir) No known interactions specific to this Protease Inhibitors combination. Refer to comments for amprenavir (Agenerase) this drug class in general fosamprenavir (Lexiva) Increases risk of kidney stones atazanivir (Reyataz) due to dehydration darunavir (Prezista) Potential to increase ecstasy levels Increases ecstasy levels 5-10 times lopinavir/ritonavir (Kaletra) (AVOID) nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) No known interactions specific to Raltegravir (Isentress) No known interactions specific to 5
6 GENERAL Erectile Dysfunction Agents (sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra)) Hypotension, tachycardia, arrhythmias (cardiac arrest and death), headache, flushing, rhinitis, dyspepsia, nausea, and visual effects (e.g. light sensitivity, changes in color vision), priapism PHARMACOKINETICS Metabolized in the liver via CYP3A4 N delavirdine (Rescriptor) Potential to significantly increase sildenafil, tadalafil, and vardenafil concentrations. Use sildenafil at nevirapine (Viramune) reduced doses of 25 mg every 48 hours, tadalafil at reduced doses of 10 mg every 72 hours, vardenafil etravirine (Intelence) at reduced doses of no more than 2.5 mg every 72 hours and monitor closely for adverse effects. No known interactions specific to. abacavir (ABC,Ziagen) Etravirine has been shown to decrease sildenafil concentrations, though may be used together without didanosine (ddl, Videx) sildenafil dosage adjustment. Sildenafil dosage may need to be adjusted based upon clinical effect. Similar interactions are also predicted with tadalafil and vardenafil. emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) SEE INDIVIDUAL COMPONENTS tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) Potential to significantly increase sildenafil, tadalafil, and vardenafil concentrations. Use sildenafil at Protease Inhibitors reduced doses of 25 mg every 48 hours, tadalafil at reduced doses of 10 mg every 72 hours, vardenafil amprenavir (Agenerase) at reduced doses of no more than 2.5 mg every 72 hours and monitor closely for adverse effects. fosamprenavir (Lexiva) No known interactions specific to. Refer to comments for this drug class in general atazanivir (Reyataz) Increases sildenafil AUC ~340% and vardenafil AUC 16-fold. May increase tadalafil concentrations. Refer darunavir (Prezista) to comments for this drug class in general. Monitor closely for adverse effects. Increases sildenafil AUC 1000%, tadalafil AUC 124%, and vardenafil AUC 49-fold and half-life 5-6 fold. lopinavir/ritonavir (Kaletra) Refer to comments for this drug class in general. Monitor closely for adverse effects. nelfinavir (Viracept) Increases sildenafil AUC ~210%. May increase tadalafil and vardenafil concentrations. Refer to comments for this drug class in general. Monitor closely for adverse effects. saquinavir (Fortovase, Invirase) No known interactions specific to Maraviroc (Selzentry) No known interactions specific to Raltegravir (Isentress) 6
7 GHB (gamma-hydroxy-butyrate, grievous bodily harm, liquid X) Seizures, bradycardia, severe respiratory GENERAL depression, hypotension, vomiting coma, death PHARMACOKINETICS Utilizes CYP2D6 pathway for metabolism N delavirdine (Rescriptor) nevirapine (Viramune) etravirine (Intelence) abacavir (ABC,Ziagen) didanosine (ddl, Videx) emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) Protease Inhibitors amprenavir (Agenerase) fosamprenavir (Lexiva) atazanivir (Reyataz) darunavir (Prezista) lopinavir/ritonavir (Kaletra) nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) Raltegravir (Isentress) No known interactions specific to SEE INDIVIDUAL COMPONENTS PIs potentially increase drug levels of GHB No known interactions specific to. Refer to comments for this drug class in general No known interactions specific to No known interactions specific to HEROIN (smack, brown junk, China White) Dreamlike state of warmth and well-being with small doses; CNS depression, drowsiness, respiratory depression, constricted pupils, nausea/vomiting with excessive doses Utilizes CYP3A4 pathway for metabolism N delavirdine (Rescriptor) nevirapine (Viramune) No known interactions specific to etravirine (Intelence) abacavir (ABC,Ziagen) SEE INDIVIDUAL COMPONENTS didanosine (ddl, Videx) emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) Possible decrease in heroin levels Protease Inhibitors amprenavir (Agenerase) No known interactions specific to fosamprenavir (Lexiva). Refer to atazanivir (Reyataz) comments for this drug class in darunavir (Prezista) general lopinavir/ritonavir (Kaletra) nelfinavir (Viracept) Reduces heroin levels by 50% saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) No known interactions specific to Raltegravir (Isentress) No known interactions specific to 7
8 KETAMINE (K, Special K) Paranoia, anxiety, mania, hallucinations, "K-hole" (semi-catatonic stupor). GENERAL Elevated levels may cause tachycardia, hypertension, respiratory depression PHARMACOKINETICS Undergoes N-demethylation and hydroxylation (possibly mediated by CYP3A4); possible weak inhibitor of CPY2D1 and CYP3A4 N delavirdine (Rescriptor) nevirapine (Viramune) etravirine (Intelence) abacavir (ABC,Ziagen) No known interactions specific to didanosine (ddl, Videx) SEE INDIVIDUAL COMPONENTS emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) Likely increase the effect of ketamine Protease Inhibitors (more sedation, increased heart rate and blood amprenavir (Agenerase) pressure). Effects last longer fosamprenavir (Lexiva) No known interactions specific to. atazanivir (Reyataz) Refer to comments for this drug class in general darunavir (Prezista) lopinavir/ritonavir (Kaletra) Combination may increase risk of drug induced hepatitis nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) No known interactions specific to 8 Raltegravir (Isentress) No known interactions specific to LSD (acid) Paranoia, visual and auditory hallucinations N delavirdine (Rescriptor) nevirapine (Viramune) etravirine (Intelence) abacavir (ABC,Ziagen) didanosine (ddl, Videx) emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) No known interactions Protease Inhibitors amprenavir (Agenerase) fosamprenavir (Lexiva) atazanivir (Reyataz) darunavir (Prezista) lopinavir/ritonavir (Kaletra) nelfinavir (Viracept) saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) Raltegravir (Isentress) No known interactions specific to this combination SEE INDIVIDUAL COMPONENTS No known interactions specific to No known interactions specific to
9 MARIJUANA (Tetrahydrocannabinol;THC) Tachycardia, loss of inhibitions, dry mouth, GENERAL visual hallucinations PHARMACOKINETICS Metabolized in the liver to active metabolite (11-hydroxy THC) via CYP3A4, 2C9, and 2C6; inhibitors/inducers of CYP3A4 may interfere with THC metabolism N delavirdine (Rescriptor) nevirapine (Viramune) etravirine (Intelence) No known interactions specific to abacavir (ABC,Ziagen) didanosine (ddl, Videx) SEE INDIVIDUAL COMPONENTS emtricitabine (FTC, Emtriva) lamivudine (3TC, Epivir) tenofovir (TDF,Viread) zidovudine (AZT, ZDV, Retrovir) P otential to increase THC levels Protease Inhibitors amprenavir (Agenerase) No known interactions specific to. fosamprenavir (Lexiva) Refer to comments for this drug class in general atazanivir (Reyataz) In one study, concentrations of atazanavir darunavir (Prezista) were reduced up to 60% in patients using marijuana. Study did not differentiate lopinavir/ritonavir (Kaletra) whether atazanavir was boosted with nelfinavir (Viracept) ritonavir or not. saquinavir (Fortovase, Invirase) Maraviroc (Selzentry) No known interactions specific to Raltegravir (Isentress) No known interactions specific to METHADONE Generalized CNS depression Primarily utilizes CYP3A4 pathway for metabolism; inhibitor of CYP2D6 and CYP3A4 N delavirdine (Rescriptor) No known interactions specific to this combination nevirapine (Viramune) etravirine (Intelence) Decreases methadone AUC significantly (~60%); titrate methadone dose to effect Decreases methadone AUC significantly abacavir (ABC,Ziagen) (~40-50%); titrate methadone dose to effect Etravirine and methadone may be used together without dosage adjustments; didanosine (ddl, Videx) monitor as needed emtricitabine (FTC, Emtriva) Increases methadone clearance ~22% (an increase in methadone dose may be required in some patients) lamivudine (3TC, Epivir) Decreases didanosine AUC ~41-60% (consider didanosine tablet form dose tenofovir (TDF,Viread) increase or switch to enteric-coated formulation which may not be affected to the same degree ) zidovudine (AZT, ZDV, Retrovir) Decreases stavudine AUC~23% Increases zidovudine AUC ~40% (increases Protease Inhibitors AUC ~29% during chronic treatment) amprenavir (Agenerase) Interaction highly variable and patients fosamprenavir (Lexiva) should be evaluated on an individual basis atazanivir (Reyataz) Decreases methadone levels ~13-30%; monitor for withdrawal and consider darunavir (Prezista) methadone dose increase if needed Decreases methadone AUC ~16-36% (may lopinavir/ritonavir (Kaletra) require methadone dose increase) nelfinavir (Viracept) Decreases methadone AUC ~26-53% (may require methadone dose increase) saquinavir (Fortovase, Invirase) Decreases methadone AUC ~47% (may require methadone dose increase) Decreases methadone AUC ~37% (may require methadone dose increase) Maraviroc (Selzentry) Decrease methadone AUC by ~50% (may require methadone dosage increase) Raltegravir (Isentress) No known interactions specific to 9
10 PATIENT INFORMATION TO REDUCE HARM ALCOHOL If you take ddi, do not drink alcohol. Try to avoid alcohol or use modestly. AMYL NITRITE (amyl nitrate, poppers) Do not use with sildenafil (Viagra), vardenafil (Levitra) or tadalafil (Cialis). Heart problems, glaucoma, or anemia make poppers more dangerous. COCAINE (coke, blow) Don t get so high you forget to stick to your antiretroviral regimen. Avoid cocaine if you have heart or liver problems, or high blood pressure Erectile Dysfunction Agents Do not mix with amyl or butyl nitrates (poppers). Combination can cause sudden drop in blood pressure leading to fainting or heart attack. GHB Start with half-teaspoon, wait half-hour before taking more. Do not mix with alcohol, tranquilizers, pain-killers, or allergy medications. Do not use if you are alone. The dose you used last week can kill you this week. KETAMINE (K, Special K) Start with 1/3 or 1/2 of usual dose. Wait a half-hour before doing more. Always use with a friend, never alone. AMPHETAMINES (Crystal) Avoid use if you have heart or liver problems, or high blood pressure. Recent reports of transmitted HIV resistance in patients using methamphetamine and practicing unsafe sex. BENZODIAZEPINES Any changes to your methadone regimen or HIV medications should be reported to both providers to ensure potential interactions are identified. ECSTASY (X, MDMA) Start with 1/4 or 1/2 tablet. Drink plenty of water. HEROIN (smack, brown junk, China, White) Start with normal dose and increase only if you experience less of a hit and less buzz. Safe injecting. Do not mix with other recreational drugs. METHADONE Any changes to your methadone regimen or HIV medications should be reported to both providers to ensure potential interactions are identified. 10
11 RESOURCES The National AETC Program also includes the following services: National HIV/AIDS Clinicians Consultation Center: Offering treating clinicians current HIV clinical and drug information and individualized, expert case consultation. Post-Exposure Prophylaxis 24 hour hotline: HIV-4911 Providing consulation for occupational exposures. Perinatal Hotline: Providing consulation for perinatal exposure and treatment. AETC HIV/AIDS National Resource Center: Providing resources (including curricula and lecture slide sets) on HIV disease treatment, education and data. 11
12 FOR FURTHER INFORMATION, PLEASE VISIT ONE OF THE FOLLOWING WEBSITES: NY/NJ AIDS Education and Training Center U.S. DHHS AIDS Info aidsinfo.nih.gov NYSDOH AIDS Institute Clinical Resources Substance Abuse and Mental Health Services Administration Addiction Technology Transfer Center Harm Reduction Coalition 12
Recreational Drugs and HIV Antivirals A Guide to Interactions for Clinicians Fall 2002
Recreational Drugs and HIV Antivirals A Guide to Interactions for Clinicians Fall 2002 Recreational Drugs and HIV Antivirals A Guide to Interactions for Clinicians Prepared by: Bruce Olmscheid, MD and
HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
HIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
ADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute
ADAP Monitoring Provider Prescribing Patterns Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute WEBINAR ETIQUETTE All questions or comments can be shared either via the
HIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
Antiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
Daclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options
STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living
0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
Antiretrovial Crushable/Liquid Formulation Chart
Antiretrovial Crushable/Liquid Formulation Chart Eliza Dollard, PharmD; Nafeesa Chin-Beckford, PharmD; Laura Aragon, PharmD Last Updated: 04/2016 Agent How Supplied Crushable Status **Products listed in
Page 1 of 5 ENLGLISH / ESPAÑOL / PORTUGUÉS / FRANÇAIS Share 3 Drug Chart for HIV Treatment CURRENT EDITION ABOUT SENSE BACK ISSUES MSMGF HOME CONTACT US There are a number of antiretroviral (ARV) medications
MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
Nobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection
Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Generic Name (Abbreviation) / Trade Name Abacavir (ABC) / Ziagen Trizivir with ZDV + 3TC Epzicom with 3TC Didanosine (ddi)
HIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time
STRATEGIES FOR FIRST LINE HIV THERAPY issues to think about when going on therapy for the first time A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Deciding
ANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids
Supportive therapy Summary of interactions Table 1. Summary of potential interactions between antiretroviral agents and supportive therapy Interactions with enzyme inhibitors (protease inhibitors and elvitegravir/cobicistat)
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
COMPLEX MENTAL HEALTH AND SUBSTANCE ABUSE. Veeral Gandhi, BSc. Phm RPh
COMPLEX MENTAL HEALTH AND SUBSTANCE ABUSE Veeral Gandhi, BSc. Phm RPh Client MF 59 year old, cis-female HIV/Hep-C EFV/TDF/FTC (since 2014) Genotype 3, Fibrosis 2 Other Medications: enalapril, metformin,
Drug Treatment Program Update
Drug Treatment Program Update As of March 211 Drug Treatment Program Update A key component of the Centre s mandate is to monitor the impact of HIV/AIDS on British Columbia. The Centre provides essential
Selecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
Adherence Strategies for Older Adults. AIDS Community Research Initiative of America (ACRIA)
Adherence Strategies for Older Adults AIDS Community Research Initiative of America (ACRIA) June 2008 Modular Objectives By the end of the module, participants will be able to: Define adherence Be able
COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
October 26-28: Training Day 1
Peer Linkage and Re-Engagement of HIV- Positive Women of Color October 26-28: Training Day 1 Peer Linkage and Re -Engagement of HIV - Positive Women of Color Convening Training Trainers Today: Alicia Downes
The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project. ARV Dosing in End Stage Renal Disease
The Annotated Bibliography of the UCSF HIV Solid Organ Transplantation Project ARV Dosing in End Stage Renal Disease 1. Jayasekara, D., Aweeka, F. T., Rodriguez, R., Kalayjian, R. C., Humphreys, M. H.,
REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO
REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO Ont. Drug Distr. Ontario Drug Benefit/Trillium: Other Formulary (F/A) Limited Use (Section 16) Antiretrovirals AZT 100 mg capsules NRTIs (single): Abacavir,
ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS
ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS - 2014 Alabama s ADAP formulary offers a minimum of one medication from each HIV antiretroviral class approved by the U.S. Food and Drug Administration (FDA).
A Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs
ADDRESSING GAPS IN INNOVATION FOR NEGLECTED PATIENTS: DNDI ANDPEDIATRIC HIV/AIDS Rachel Cohen, Regional Executive Director, DNDi North America Proposals for a Global Innovation System that Responds to
HIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.
Avifanz Tablet Description Avifanz is the brand name for Efavirenz. Efavirenz, a synthetic antiretroviral agent, is a non-nucleoside reverse transcriptase inhibitor. While Efavirenz is pharmacologically
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop
HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop Parya Saberi, PharmD, MAS The Medical Management of HIV/AIDS December 2012 Objectives What are commonly used ARVs and where do they work in
Addressing Pediatric Needs of the Most Neglected: next steps
Addressing Pediatric Needs of the Most Neglected: next steps An updated overview of DNDi Pediatric Focus Nathalie Strub Wourgaft (Medical Director) Janice Lee (HIV Pediatric Clinical Manager) A Fatal Imbalance
NON-OCCUPATIONAL POST EXPOSURE PREVENTION. when you think you were exposed to hiv within the past three days
NON-OCCUPATIONAL POST EXPOSURE PREVENTION when you think you were exposed to hiv within the past three days A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY
Nothing to disclose.
Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital HIV UPDATE FOR THE PRIMARY CARE PROVIDER Nothing to disclose. 1 Outline Epidemiology Screening / testing for HIV
104 MMWR December 17, 2004
104 MMWR December 17, 2004 TABLE 8. Substantial pharmacokinetic drug-drug interactions for drugs used in the treatment of opportunistic Drugs Interacting with Mechanism/effects Recommendations Acyclovir
An HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
Quick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents
Author: Malte Schütz, MD June 1, 2002 Quick Reference Guide to Antiretrovirals Regular updates to this publication are posted on the Medscape Web site at http://hiv.medscape.com/updates/quickguide. Please
Medication Errors Focus on the HIV-Infected Patient
Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation
Human Immunodeficiency Virus Infection A Modern Day Epidemic
Human Immunodeficiency Virus Infection A Modern Day Epidemic Frank Romanelli, PharmD, MPH, BCPS Assistant Dean and Associate Professor of Pharmacy Clinical Specialist in HIV/AIDS University of Kentucky
Continuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
HIV Infection & AIDS in Low- and Middle-Income Countries
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 25: HIV Infection & AIDS in Low- and Middle-Income Countries Author P. Van de Perre, MD, PhD Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
Objectives. HIV Treatment in Recently In 1996 the introduction of protease inhibitors decreasing the death rate of those infected by 50%.
Objectives Identify modes HIV transmission and methods of prevention. HIV Treatment in 2010 Lisa D. Inge, Pharm.D., BCPS, AAHIVE Assistant Director, Jacksonville Campus Clinical Assistant Professor University
HIV/AIDS Update 2007
HIV/AIDS Update 2007 Joanne J. Orrick, Pharm.D., BCPS Clinical Assistant Professor University of Florida Faculty, Florida/Caribbean AIDS Education and Training Center orricjj@ufl.edu www.faetc.org orricjj@ufl.edu
FLORIDA!A MEDICAID' Better Health Care for all Floridians. May
CHARLIE CRIST GOVERNOR FLORIDA!A MEDICAID' Better Health Care for all Floridians HOllY BENSON SECRETARY May 26. 2009 Policy Transmittal: HMO 09-01 Policy Transmittal: PS 09-01 RE: Year Thrcc PerFormance
P.I. Perspective. December 2008, Issue #47. Information, Inspiration and Advocacy for People Living with HIV/AIDS
P.I. Perspective December 2008, Issue #47 Information, Inspiration and Advocacy for People Living with HIV/AIDS This issue of PI Perspective represents Project Inform s coverage of the joint 2008 ICAAC
Approach for the Newly Diagnosed HIV Positive Patient
Approach for the Newly Diagnosed HIV Positive Patient Jason E. Farley, PhD, MPH, ANP-BC, FAAN, AACRN Associate Professor & NP, Johns Hopkins University School of Nursing & Medicine Director, AETC Adult-Gerontology
Simplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
The ART of Antiretroviral Therapy in Critically-ill Patients with HIV
The ART of Antiretroviral Therapy in Critically-ill Patients with HIV Tyler Finocchio, PharmD, BCPS PGY2 Critical Care Pharmacy Resident Avera McKennan Hospital & University Health Center February 10 th,
Antiretroviral Pregnancy Registry
Preterm Birth, low birth weight and fetal antiretroviral exposure: Estimated gestational age and birth weight data from singleton live births, 1989 through 31 January 2009 K. Beckerman, J. Albano, M. Martinez-Tristani,
JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet
JULUCA (dolutegravir sodium-rilpivirine hydrochloride) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course
Overview of HIV WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments - Dr. Christina Polyak - Dr. Julie Ake Disclaimer The views expressed in this presentation are
Appropriate Use & Safety Edits
Appropriate Use & Safety Edits Envolve Pharmacy Solutions provides a variety of safety edits to promote the use of the right medication, in the right patient, at the right time. These edits are routinely
MEDICATION RELATED ISSUES IN THE HIV PATIENT. LEONARD SOWAH, MBChB, MPH, FACP
MEDICATION RELATED ISSUES IN THE HIV PATIENT LEONARD SOWAH, MBChB, MPH, FACP Overview Evalua;on and ini;al of a HIV pa;ent with respect to medica;ons Triaging of pa;ent to determine ideal follow up plan
Blood-Borne Pathogens and Post-Exposure Prophylaxis
Blood-Borne Pathogens and Post-Exposure Prophylaxis Christopher Behrens MD Northwest Association of Occupational and Environmental Medicine October 2017 with thanks to Shireesha Dhanireddy MD Disclosures
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search
BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search Search 1 :When to Initiate ART Covers Questions 1-5 including to prevent transmission Component Description Review area Objectives
HIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2012 EDURANT 25 mg film-coated tablets B/30 (CIP code: 219 472-9) Applicant: JANSSEN-CILAG rilpivirine ATC code
PROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY
PROGRESSIVE MULTI-FOCAL LEUKOENCEPHALOPATHY learn about the symptoms, diagnosing and treating this relatively rare brain condition associated with aids A PUBLICATION FROM Information, Inspiration and Advocacy
ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting
ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions
Overview of HIV. LTC Paige Waterman
Overview of HIV LTC Paige Waterman Outline Background and Epidemiology HIV Virology, Transmission, and Pathogenesis Acute HIV infection HIV Diagnostics Management of Health Care Personnel Exposed to HIV
Industry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
The Hospitalized HIV+ Patient
The Hospitalized HIV+ Patient Danny Toub MD dannyt@srheathcenters.org October 8, 2012 Santa Rosa Family Medicine Residency List 3 ways of risk-stratifying known or suspected HIV+ inpatients Perform differential
Pharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
The ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
Recommended dosing for pediatric patients (6 months to 12 years of age) 1. Dose based on lopinavir component* 1.25 ml ml
Abbott Virology 100 Abbott Park Road Abbott Park, IL 60064 KALETRA 100/25 mg tablets NDC #0074-0522-60 Dear Healthcare Provider: Introducing a new strength of KALETRA (lopinavir/ritonavir): 100/25 mg tablets
Section 6: Treatment of Hepatitis C virus (HCV)
Section 6: Treatment of Hepatitis C virus (HCV) Dr. Niklas Luhmann (Médecins du Monde) Training Hepatitis C and HR for PWUD, 9 th -13 th May 2016, Hanoi, Vietnam Learning objective of the session: understanding
Friday afternoon Programme
Friday afternoon Programme Pharmacology and TDM Dr Marta Boffito Consultant Physician, C&W Resistance to new anti-retrovirals Dr Steve Taylor Consultant Physician, Birmingham HIVPA Annual Conference 2008
New Frontiers for Treatment Strategies for HIV Care
New Frontiers for Treatment Strategies for HIV Care Eric S. Daar, MD Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Disclosures:
Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos
Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos (Antiretroviral Therapy Present and Future Prospects of Antiretroviral Drugs in Initial and Salvage Therapy)
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
continuing education for pharmacists
continuing education for pharmacists HIV/AIDS: Overview and Resources for Pharmacists Mona T. Thompson, R.Ph., PharmD Volume XXXIII, No. 9 Dr. Mona T. Thompson has no relevant financial relationships to
SUMMARY OF PRODUCT CHARACTERISTICS
Section 6 updated: March 2017 SUMMARY OF PRODUCT CHARACTERISTICS 1 Section 6 updated: March 2017 1. NAME OF THE MEDICINAL PRODUCT Ritonavir Tablets 100 mg * 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D.
Approach to a Patient Newly Diagnosed with HIV, Including ART Basics Rajesh T. Gandhi, M.D. Disclosures: grant support from Gilead, Roche, EBSCO Objectives Apply current guidelines to initial evaluation
STATEMENT OF DISCLOSURE
STATEMENT OF DISCLOSURE Presenter has no relevant financial relationships with commercial interests pertaining to the contents of this program ARB 2 OBJECTIVES Define medication errors and discuss data
The New Agents: Management of Experienced Patients and Resistance. Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine
The New Agents: Management of Experienced Patients and Resistance Joel E. Gallant, MD, MPH Johns Hopkins University School of Medicine T.D. 45 year old man with HIV infection diagnosed in 2000 On multiple
TB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
Human Immunodeficiency Virus (HIV)
HIV INFECTION! Human Immunodeficiency Virus (HIV) Infects human cells and causes gradual loss of immune system function, and these immune alterations predispose to the opportunistic infections, neoplasms,
Comprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
An Update on HIV Therapy Protease Inhibitors for Treatment Experienced Patients
Page 1 An Update on HIV Therapy Protease Inhibitors for Treatment Experienced Patients An Update on HIV Therapy Protease Inhibitors for Treatment Experienced Patients Speaker: This lecture is being co-presented
30 Years of HIV: An Update on Treatment Guidelines and Beyond
8/3/212 Conflict of Interest Declaration 3 Years of HIV: An Update on Treatment Guidelines and Beyond Blake Max, PharmD, AAHIVE Clinical Associate Professor University of Illinois at Chicago College of
World AIDS Day Year-by-Year Milestones in HIV/AIDS. healthlibrary
World AIDS Day 2014 Year-by-Year Milestones in HIV/AIDS (Adapted from The POZ Timeline: Milestones in the HIV/AIDS Pandemic with additions compiled by Eric Brus, Director of HIV Health Promotion, AIDS
Drug Interactions. Together, we can change the course of the HIV epidemic one woman at a time.
Drug Interactions Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject Drug Interactions Some drugs, herbs, supplements, foods, beverages can change
Understanding Viruses CHAPTER 38. Antiviral Agents. Understanding Viruses (cont'd) Viral Infections (cont'd) Viral Infections.
Understanding Viruses CHAPTER 38 Antiviral Agents Viral replication A virus cannot replicate on its own It must attach to and enter a host cell It then uses the host cell s energy to synthesize protein,
Genotyping and Drug Resistance in Clinical Practice. Case Studies
Genotyping and Drug Resistance in Clinical Practice Case Studies 12/02 40 year old Hispanic male Dx with HIV 1995 + Hx of PCP > 1x, HepC Medication history: AZT, Crixivan, Videx EC, Sustiva, Zerit, Ziagen,
NATAPNATIONAL. HIV 102: Care & Treatment AIDS TREATMENT ADVOCACY PROJECT. Origins of HIV. Table of Contents. National AIDS Treatment Advocacy Project
National AIDS Treatment Advocacy Project HIV 102: Care & Treatment Written by: Jose Castro, MD University of Miami, Miller School of Medicine, Miami, FL Editorial Contributions by: Jules Levin 580 BROADWAY,
Matters of the HAART: An Update on Current Treatment Options for HIV
Matters of the HAART: An Update on Current Treatment Options for HIV Jason Alegro, PharmD, BCPS Assistant Professor of Clinical Sciences, Roosevelt University Infectious Diseases Clinical Pharmacy Specialist,
Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants
Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants Mark Mirochnick, MD Boston University School of Medicine, Boston, MA, USA Full Term Full Term 34 wks
what's with it? GOT TO DO [Pharmacokinetics] [Pharmacokinetics] Non-Nukes and PIs: Do They Play Well Together? / Top 3 Websites Winter 2005
![what's with it? GOT TO DO [Pharmacokinetics] [Pharmacokinetics] Non-Nukes and PIs: Do They Play Well Together? / Top 3 Websites Winter 2005](/thumbs/75/71794673.jpg "what's with it? GOT TO DO [Pharmacokinetics] [Pharmacokinetics] Non-Nukes and PIs: Do They Play Well Together? / Top 3 Websites Winter 2005")
Winter 2005 what's PK [Pharmacokinetics] [Pharmacokinetics] GOT TO DO with it? IN THIS SPECIAL ISSUE: ABC's of Pharmacokinetics (PK) / The Nukes, Non-Nukes and PIs: Do They Play Well Together? / Top 3
Exploring HIV in 2017: What a pharmacist needs to know
Exploring HIV in 2017: What a pharmacist needs to know Lifecycle of the HIV virus a. HIV spread through mucous membrane contact, damaged tissue contact, or blood contact with: blood, semen, rectal fluids,
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman